NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Leverages New Financing And IP Control Is Its Gene-Editing Edge Strengthening?
Beam Therapeutics recently reported a swing to fourth-quarter 2025 net income of US$244.3 million and entered a long-term, up-to-US$500 million credit facility with Sixth Street to support its sickle cell gene-editing candidate, while also filing a US$144.13 million shelf registration tied to an employee stock plan.
At the same time, Beam preserved exclusive access to core base-editing intellectual property through a direct Kobe University license after ending its cross-license with Bio...